Hypercholesterolaemia and its management

  title={Hypercholesterolaemia and its management},
  author={Deepak Bhatnagar and Handrean Soran and Paul N. Durrington},
  journal={BMJ : British Medical Journal},
Hypercholesterolaemia is one of the major causes of atherosclerosis. Although there are many causes, hypercholesterolaemia is the permissive factor that allows other risk factors to operate.1 The incidence of coronary heart disease is usually low where population plasma cholesterol concentrations are low.2 In Britain coronary heart disease is a major cause of mortality, and a recent Department of Health survey suggested that the average plasma cholesterol concentration in the United Kingdom was… 
The global increase in the prevalence of hyperlipidemia is due to unhealthy eating habits, obesity and physical inactivity, and the emergencies, risk factors and remedies are described in the literature.
Mortality for individuals with familial hypercholesterolemia(FH) in the period 1992-2010.
At age 0-59, cancer and none-CVD death cause had lower total SMR among FH individuals, than the general population, and individuals with FH have higher prevalence of death by CVD, thanThe general population.
A complete overview on dyslipidemia, its impact on the progression of cardiovascular diseases, its various forms, pharmacological interventions involved in its treatment and most recent investigations which are fruitful in the understanding of the disease and helpful to take preventive measures for cardiovascular diseases are reviewed.
High-density lipoprotein cholesterol raising: does it matter?
There is evidence to support the view that HDL functionality and the mechanism by which a therapeutic agent raises HDL-C are more important than plasma cholesterol levels, rather than simply raising the cholesterol cargo.
Cascade screening for familial hypercholesterolaemia and its effectiveness in the prevention of vascular disease
How cascade screening for familial hypercholesterolaemia will be implemented into primary and secondary care, its potential advantages and disadvantages, and how it will help to prevent myocardial infarctions in patients with FH are considered.
Molecular aspects of hypercholesterolemia treatment: current perspectives and hopes
The molecular aspects of current and novel therapeutic approaches based on low-density lipoprotein cholesterol lowering strategies and the most common genes involved in hypercholesterolemia are LDLR, PCSK9 and ApoB are reviewed.
A Review on Hyperlipidemic
The most recent cholesterol management guidelines (the third report of the adult treatment panel APT III), which are issued by the national cholesterol education program (NCEP) in may 2001, redefine the levels at which blood cholesterol should be treated and are departure from the NCEP's previous guidelines (ATP II).
The Effect of Nephelium longata L Honeyconsumption on Decreasing of Cholesterol Level for Hypercholesterolemia Patient at Medical Clinic of Farras Husada of Sowan Lor, Kedung, Jepara
There was a significant effect of honey Nephelium longata L consumption to decrease cholesterol levels in the intervention group and there is effect on cholesterol lowering in the control group.
Severe hypercholesterolemia mediated by lipoprotein X in a patient with cholestasis.
This case highlights the significance of LpX as a cause of severe hypercholesterolemia in a patient with cholestasis secondary to a granulomatous hepatitis attributed to tuberculosis.
An Overview on Hyperlipidemia
This review is useful to research work in hyperlididemia and statins and fibrates remain the most common anti-hyperlipidemic drugs for treating high plasma cholesterol and triglycerides.


Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations.
Blood cholesterol concentration was directly related to mortality from coronary heart disease even in those with what was, by Western standards, a "low" cholesterol concentration.
The safety of statins in clinical practice
Diagnosis and screening for familial hypercholesterolaemia: finding the patients, finding the genes
Clinicians need to be made more aware of the clinical features of FH and how to diagnose it in order to increase the index of suspicion and instigate appropriate treatment early, with the aim of preventing premature coronary heart disease.
Indications for cholesterol-lowering medication: comparison of risk-assessment methods
Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds.
  • S. Grundy
  • Medicine, Biology
    Journal of the American College of Cardiology
  • 2006
Human cholesterol metabolism and therapeutic molecules.
Drugs which interfere with hepatic very low-density lipoprotein assembly in the liver, such as microsomal triglyceride transfer protein inhibitors and apolipoprotein B mRNA antisense oligonucleotides, are currently undergoing evaluation, and Cholesteryl ester transfer protein (CETP) inhibitors, which decrease cholesteryl Ester heteroexchange within the circulation, have undergone development to the point of clinical evaluation.
Risk for myopathy with statin therapy in high-risk patients.
Clinicians should be alert to the potential for drug-drug interactions to minimize the risk of myopathy during long-term statin therapy in patients at high risk for coronary heart disease.
Outcome of case finding among relatives of patients with known heterozygous familial hypercholesterolaemia
By performing cholesterol tests on 200 relatives, 121 new patients with familial hypercholesterolaemia were discovered, and only a few of these patients would have been detected had cholesterol testing been restricted to those with other risk factors for coronary heart disease.
Coronary Artery Disease in 116 Kindred with Familial Type II Hyperlipoproteinemia
This study, the largest of its kind, permitted more precise and extensive determination of the CAD risk accompanying severe hyperbetalipoproteinemia than has heretofore been possible.
Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis
Statins can lower LDL cholesterol concentration by an average of 1.8 mmol/l which reduces the risk of IHD events by about 60% and stroke by 17% and is corroborated by results from the nine cohort studies.